Biology Reference
In-Depth Information
dema F. 2000a. Increased cell division but not thymic dysfunction rapidly a¨ects the T-cell
receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med 6:
1036±1042.
Hazenberg MD, Hamann D, Schuitemaker H, Miedema F. 2000b. T cell depletion in HIV-1
infection: how CD4
T cells go out of stock. Nat Immunol 4: 285±289.
Hellerstein MK, McCune JM. 1997. T cell turnover in HIV-1 disease. Immunity 7: 583±589.
Hellerstein M, Hanley MB, Cesar D, Siler S, Papageorgopoulos C, Wieder E, Schmidt D, Hoh R,
Neese R, Macallan D, Deeks S, McCune JM. 1999. Directly measured kinetics of circulating T
lymphocytes in normal and HIV-1 infected humans. Nat Med 5: 83±89.
Hengge UR, Goos M, Esser S, Exner V, Dotterer H, Wiehler H, Borchard C, Muller K, Beckmann
A, Eppner MT, Berger A, Fiedler M. 1998. Randomized, controlled phase II trial of subcuta-
neous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV
patients. AIDS 12: F225±F234.
Ho D, Neumann AV, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995. Rapid turnover of
plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123±126.
Hogg RS, O'Shaughnessy MW, Gataric N, Yip B, Craib K, Schechter MT, Montaner JS. 1997.
Decline in deaths from AIDS due to new antiretrovirals. Lancet 349: 1294.
Imami N, Hardy GA, Nelson MR, Morris Jones S, Al Shahi R, Antonopoulos C, Gazzard B,
Gotch FM. 1999. Induction of HIV-1-speci®c T cell responses by administration of cytokines
in late-stage patients receiving highly active antiretroviral therapy. Clin Exp Immunol 118: 78±
86.
Jacobson MA, Zegans M, Pavan PR, O'Donnell JJ, Sattler F, Rao N, Owens S, Pollard R. 1997.
Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 349:
1443±1445.
Jones JL, Hanson DL, Dworkin MS, Ward JW, Ja¨e HW. 1999. E¨ect of antiretroviral therapy on
recent trends in selected cancers among HIV-infected persons. Adult/Adolescent Spectrum of
HIV Disease Project Group. J Acquir Immune De®c Syndr 21 (Suppl 1): S11±S17.
Jouan M, Saves M, Tubiana R, Carcelain G, Olivier C, Autran B, RESTIMOP (ANRS 078). 2001.
A multicenter prospective study to evaluate the discontinuation of maintenance therapy for
CMV retinitis in HIV-patients receiving HAART. AIDS 15: 23±31.
Kalams S, Walker B. 1998. The critical need for CD4 help in maintaining e¨ective cytotoxic T
lymphocytes responses. J Exp Med 188: 2199±2204.
Katlama C, Duvivier C, Chouquet C, Autran A, Carcelain G, de Sa L, Zagury M, Costagliola D,
Tubiana R. 2000. ILSTIM (ANRS 082). A randomized comparative open-label study of inter-
leukin (IL2) in patients with CD4 < 200/mm
3
despite e¨ective HAART [abstract]. 7th Confer-
ence on Retroviruses and Opportunistic Infections, San Francisco, CA.
Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, Rasheed S, Elbeik
T, Reichman R, Japour A, Merigan TC, Hirsch MS. 1996. The relation of virologic and im-
munologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with
200 to 500 CD4 cells per cubic millimeter. N Engl J Med 335: 1091±1098.
Kaufmann D, Pantaleo G, Sudre P, Telenti A. 1998. CD4-cell count in HIV-1-infected individuals
remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort
Study [letter]. Lancet 351: 723±724.
Komanduri KV, Viswanathan MV, Wieder ED, Schmidt DK, Bredt BM, Jacobson MA, McCune
JM. 1998. Restoration of cytomegalovrius-speci®c CD4
T-lymphocyte responses after ganci-
clovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 4:
953±956.
Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT, Walker RE, Polis MA, Spooner K, Metcalf
JA, Baseler M, Fyfe G, Lane HC. 1996. Controlled trial of interleukin-2 infusions in patients
infected with the human immunode®ciency virus. N Engl J Med 335: 1350±1356.
